Lai-ping J. Zhong

Department Of Oromaxillofacial Head And Neck Surgery, Center For Oromaxillofacial Head And Neck Disorders
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Luvometinib in patients with Langerhans cell histiocytosis, Erdheim-Chester disease, and other histiocytic neoplasms: a single-arm, multicentre, phase 2 study.

Luvometinib in patients with Langerhans cell histiocytosis, Erdheim-Chester disease, and other histiocytic neoplasms: a single-arm, multicentre, phase 2 study.

Journal: EClinicalMedicine

Published: June 26, 2025

The emerging role of neoadjuvant immunotherapy in locally advanced oral squamous cell carcinoma: progress and challenges.

The emerging role of neoadjuvant immunotherapy in locally advanced oral squamous cell carcinoma: progress and challenges.

Journal: International journal of surgery (London, England)

Published: May 20, 2025

Macrophage-Capturing Self-Assembly Photosensitizer Nanoparticles Induces Immune Microenvironment Re-Programming and Golgi-Responsive Immunogenic Cell Death in Head and Neck Carcinoma.

Macrophage-Capturing Self-Assembly Photosensitizer Nanoparticles Induces Immune Microenvironment Re-Programming and Golgi-Responsive Immunogenic Cell Death in Head and Neck Carcinoma.

Journal: Advanced healthcare materials

Published: January 02, 2024

Personalized therapy for Helicobacter pylori on initial treatment: the initial treatment is the decisive battle

Personalized therapy for Helicobacter pylori on initial treatment: the initial treatment is the decisive battle

Journal: Zhonghua yi xue za zhi

Published: June 12, 2022

Experimental investigation of vincristine on chemosensitivity through Stathmin regulation in oral squamous cell carcinoma

Experimental investigation of vincristine on chemosensitivity through Stathmin regulation in oral squamous cell carcinoma

Journal: Shanghai kou qiang yi xue = Shanghai journal of stomatology

Published: May 19, 2022

Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.

Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.

Journal: Cancer science

Published: July 08, 2021

Targeting ERK combined with apatinib may be a promising therapeutic strategy for treating oral squamous cell carcinoma.

Targeting ERK combined with apatinib may be a promising therapeutic strategy for treating oral squamous cell carcinoma.

Journal: American journal of cancer research

Published: January 21, 2021

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.

Journal: The Lancet. Oncology

Published: November 23, 2020

Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo.

Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo.

Journal: Translational oncology

Published: November 18, 2020

Standardized and individualized diagnosis and treatment of oral squamous cell carcinoma: opportunities and challenges

Standardized and individualized diagnosis and treatment of oral squamous cell carcinoma: opportunities and challenges

Journal: Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology

Published: October 21, 2020

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: October 15, 2020

Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome.

Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome.

Journal: Cancer communications (London, England)

Published: September 22, 2020

Showing 1-12 of 39

Last Updated: 09/26/2026